MX2021013442A - Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma. - Google Patents
Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma.Info
- Publication number
- MX2021013442A MX2021013442A MX2021013442A MX2021013442A MX2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A
- Authority
- MX
- Mexico
- Prior art keywords
- transnasal administration
- powder preparation
- producing same
- preparation
- transnasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019093150 | 2019-05-16 | ||
| PCT/JP2020/018456 WO2020230676A1 (ja) | 2019-05-16 | 2020-05-01 | 経鼻投与用の粉末製剤及びその製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013442A true MX2021013442A (es) | 2022-01-06 |
Family
ID=73290206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013442A MX2021013442A (es) | 2019-05-16 | 2020-05-01 | Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12478581B2 (https=) |
| EP (1) | EP3970696A4 (https=) |
| JP (2) | JPWO2020230676A1 (https=) |
| KR (1) | KR20220009407A (https=) |
| CN (1) | CN113784703A (https=) |
| AU (1) | AU2020273810B2 (https=) |
| BR (1) | BR112021021841A2 (https=) |
| CA (1) | CA3138846A1 (https=) |
| MX (1) | MX2021013442A (https=) |
| WO (1) | WO2020230676A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250270471A1 (en) * | 2022-04-21 | 2025-08-28 | Merck Sharp & Dohme Llc | Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts |
| CN117503703B (zh) * | 2023-11-09 | 2024-11-22 | 广州新济药业科技有限公司 | 一种左旋多巴鼻喷雾剂及其制备方法及应用 |
| WO2025225629A1 (ja) * | 2024-04-23 | 2025-10-30 | 株式会社メディラボRfp | 経鼻投与用組成物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993012818A1 (fr) * | 1991-12-27 | 1993-07-08 | Daiichi Pharmaceutical Co., Ltd. | Preparation pharmaceutique pour application topique |
| JP3634380B2 (ja) * | 1996-02-27 | 2005-03-30 | 帝人株式会社 | 粉末状経鼻投与組成物 |
| JP3197221B2 (ja) * | 1996-02-27 | 2001-08-13 | 帝人株式会社 | 吸収性が改善された粉末状経鼻投与組成物 |
| JP3197222B2 (ja) | 1996-02-28 | 2001-08-13 | 帝人株式会社 | 粉末状経鼻投与組成物 |
| JP3197223B2 (ja) * | 1996-02-28 | 2001-08-13 | 帝人株式会社 | 即効性と持続性を兼ね備えた粉末状経鼻投与用組成物 |
| JP2001055323A (ja) * | 1999-08-12 | 2001-02-27 | Teijin Ltd | 粉末状経鼻投与用組成物 |
| JP4711520B2 (ja) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
| KR20030027108A (ko) * | 2001-07-05 | 2003-04-03 | 트렌스레셔널 리서치 가부시키가이샤 | 인슐린의 경비 투여용 조성물 |
| WO2006016530A1 (ja) | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| JPWO2006064906A1 (ja) | 2004-12-17 | 2008-06-12 | 小野薬品工業株式会社 | 非晶質性組成物 |
| JP2006176461A (ja) * | 2004-12-24 | 2006-07-06 | Dai Ichi Seiyaku Co Ltd | 粒状物 |
| ITRM20050443A1 (it) | 2005-08-12 | 2007-02-13 | Opocrin Spa | Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea. |
| CA2672134C (en) * | 2006-12-07 | 2015-02-10 | Daiichi Sankyo Company, Limited | Solid medicinal preparation containing mannitol or lactose |
| US8337817B2 (en) * | 2006-12-26 | 2012-12-25 | Shin Nippon Biomedical Laboratories, Ltd. | Preparation for transnasal application |
| CN101428009B (zh) * | 2008-04-09 | 2013-01-09 | 上海医药工业研究院 | 胰岛素经鼻吸入粉雾剂 |
| WO2009135646A2 (en) | 2008-05-05 | 2009-11-12 | Farmaprojects, Sa | Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
| WO2010131486A1 (en) * | 2009-05-15 | 2010-11-18 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| ES2663335T3 (es) | 2010-03-19 | 2018-04-12 | Daiichi Sankyo Company, Limited | Composición para administración transnasal y método para prepararla |
| JP2017036214A (ja) * | 2013-12-10 | 2017-02-16 | 株式会社ダイセル | 炭酸塩を含む口腔内崩壊錠剤用組成物及び口腔内崩壊錠剤 |
| KR102634829B1 (ko) * | 2016-06-24 | 2024-02-07 | 오피언트 파마슈티컬스, 인코퍼레이티드 | 알코올 사용 장애의 치료용 조성물, 장치 및 방법 |
| EP3493789A2 (en) * | 2016-08-05 | 2019-06-12 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| US11135217B2 (en) * | 2016-12-26 | 2021-10-05 | Shionogi & Co., Ltd. | Manufacturing process of formulation having improved content uniformity |
| US11744967B2 (en) * | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
-
2020
- 2020-05-01 CN CN202080032083.6A patent/CN113784703A/zh active Pending
- 2020-05-01 WO PCT/JP2020/018456 patent/WO2020230676A1/ja not_active Ceased
- 2020-05-01 AU AU2020273810A patent/AU2020273810B2/en active Active
- 2020-05-01 EP EP20806255.4A patent/EP3970696A4/en active Pending
- 2020-05-01 JP JP2021519385A patent/JPWO2020230676A1/ja active Pending
- 2020-05-01 KR KR1020217040454A patent/KR20220009407A/ko not_active Ceased
- 2020-05-01 MX MX2021013442A patent/MX2021013442A/es unknown
- 2020-05-01 CA CA3138846A patent/CA3138846A1/en active Pending
- 2020-05-01 BR BR112021021841A patent/BR112021021841A2/pt unknown
- 2020-05-01 US US17/595,381 patent/US12478581B2/en active Active
-
2024
- 2024-06-20 JP JP2024099620A patent/JP2024111203A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024111203A (ja) | 2024-08-16 |
| EP3970696A4 (en) | 2023-03-01 |
| EP3970696A1 (en) | 2022-03-23 |
| US12478581B2 (en) | 2025-11-25 |
| BR112021021841A2 (pt) | 2022-01-04 |
| US20220183971A1 (en) | 2022-06-16 |
| JPWO2020230676A1 (https=) | 2020-11-19 |
| CN113784703A (zh) | 2021-12-10 |
| AU2020273810A1 (en) | 2021-11-18 |
| WO2020230676A1 (ja) | 2020-11-19 |
| AU2020273810B2 (en) | 2025-10-09 |
| KR20220009407A (ko) | 2022-01-24 |
| CA3138846A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170361A (es) | Forma de dosificación que incluye una solución sólida de drogas amorfas | |
| CL2018002914A1 (es) | Formas de dosificación de liberación modificada disuasivas de abuso. | |
| BR112017023674A2 (pt) | suspensões farmacêuticas contendo partículas de fármaco, dispositivos para sua administração, e métodos de seu uso | |
| CL2018000739A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma. | |
| CL2015003346A1 (es) | Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas | |
| MX2021013442A (es) | Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma. | |
| ECSP17053843A (es) | Formulación nasal en polvo para el tratamiento de hipoglicemia | |
| AR087871A1 (es) | Una composicion farmaceutica de rapida disolucion | |
| IN2013MU03583A (https=) | ||
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| CR20150637A (es) | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral | |
| MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
| CL2015003468A1 (es) | Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
| CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| MX349920B (es) | Producción de principios farmacéuticos activos estériles. | |
| MX2016015208A (es) | Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen. | |
| AR101673A1 (es) | Composición para el tratamiento de neuropatías y del dolor neuropático | |
| MX386987B (es) | Mini-tabletas de melatonina y métodos de fabricación de las mismas. | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| MX2019010229A (es) | Composicion para la liberacion controlada de sustancias fisiologicamente activas y proceso para su preparacion. | |
| AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
| BR112017019364A2 (pt) | dispersões sólidas |